FOLH1 and cancer: Epidermal growth factor receptor (EGFR), prostate-specific membrane antigen (PSMA), and human epidermal growth factor receptor 2 (HER2) have emerged as three prominent targets for MAB-functionalized NPs in cancer therapy, which have been extensively investigated in recent years [134–136].